Full text is available at the source.
Abstract
Inhalable gene-loaded lipid nanoparticles (LNPs) may provide a promising direction for disease-modifying therapy in idiopathic pulmonary fibrosis (IPF).
- Idiopathic pulmonary fibrosis is characterized by excessive accumulation of extracellular matrix and lung tissue remodeling.
- Current antifibrotic therapies have limited effectiveness in modifying the disease.
- Advancements in lipid nanoparticle platforms, such as solid lipid nanoparticles and liposomes, are being investigated for delivering nucleic acid therapies directly to the lungs.
- Targeting transforming growth factor-β (TGF-β) signaling through inhalable LNPs could modulate gene expression in IPF.
- LNP-mediated delivery of CRISPR components may enable long-lasting gene editing with reduced systemic toxicity.
Simplified